Impel Pharmaceuticals Inc.
IMPL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $88 | $126 | $197 | $197 |
| - Cash | $61 | $88 | $7 | $37 |
| + Debt | $51 | $29 | $8 | $0 |
| Enterprise Value | $78 | $67 | $198 | $160 |
| Revenue | $13 | $1 | $0 | $0 |
| % Growth | 1,794% | – | – | – |
| Gross Profit | $6 | -$0 | $0 | $0 |
| % Margin | 48.7% | -3.4% | – | – |
| EBITDA | -$91 | -$70 | -$44 | -$41 |
| % Margin | -721.4% | -10,538.6% | – | – |
| Net Income | -$129 | -$77 | -$46 | -$42 |
| % Margin | -1,023.1% | -11,457.5% | – | – |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| % Growth | -5.3% | -50.1% | -9.4% | – |
| Operating Cash Flow | -$94 | -$66 | -$39 | -$36 |
| Capital Expenditures | -$1 | -$0 | -$2 | -$2 |
| Free Cash Flow | -$95 | -$67 | -$41 | -$38 |